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INTRODUCTION 
 
Cerebral blood flow is pivotal for providing oxygen and 
nutrients to the brain to maintain brain function. The 
brain is a highly metabolically active organ but has only 
limited possibilities for energy storage. Thus, cerebral 
blood flow is important because the brain depends on 
constant and regulated blood supply to function 
properly. With aging, pathophysiological changes occur 
in large arteries causing decreased ability of large 
arteries to absorb and dampen pulsatile blood flow, 
eventually leading to pulsatile stress and arterial 
stiffness [1]. Transmission of increased pulsatile stress 
to the brain microvasculature is thought to lead to 
increased microvascular brain damage via altered 
dampening of pulsatile blood flow in cerebral arteries, 
and is considered a contributing factor for some 
cerebrovascular diseases [2]. 
 
Insulin influences all aspects of human physiology, 
including central regulation of energy homeostasis, 
cognitive functions and neuronal activity [3, 4]. The 
central regulation of energy homeostasis involves a 
complex neuronal network, which comprises the 
hypothalamus, the thalamus as well as cortical brain 
structures. Insulin and its signaling have been 
consistently linked to aging, lifespan and longevity [5, 
6]. Aging is associated with reduced insulin action in 
peripheral tissues and possibly in the brain. Reduced 
insulin action in the aging brain may relate to age- 
associated cognitive defects and anomalies of metabolic 
homeostasis and an accelerated pace of aging [7-10]. 
Recent data suggest that insulin is also a vasoactive 
modulator that regulates peripheral and cerebral blood 
flow, possibly via a direct vasodilatory effect [11]. 
Reduced insulin action has been associated with 
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ABSTRACT 
 
Insulin, a vasoactive modulator regulating peripheral and cerebral blood flow, has been consistently linked to 
aging and longevity. In this proof of principle study, using a randomized, double-blinded, placebo-controlled 
crossover design, we explored the effects of intranasally administered insulin (40IU) on cerebral blood flow 
(CBF) and perfusion in older (60-69 years, n=11) and younger (20-26 years, n=8) adults. Changes in CBF through 
the major cerebropetal arteries were assessed via phase contrast MR-angiography, and regional cortical tissue 
perfusion via pseudo-continuous arterial spin labelling. Total flow through the major cerebropetal arteries was 
unchanged in both young and old. In the older participants, intranasal insulin compared to placebo increased 
perfusion through the occipital gray matter (65.2±11.0 mL/100g/min vs 61.2±10.1 mL/100g/min, P=0.001), and 
in the thalamus (68.28±6.75 mL/100g/min versus 63.31±6.84 mL/100g/min, P=0.003). Thus, intranasal insulin 
improved tissue perfusion of the occipital cortical brain region and the thalamus in older adults. 
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vascular impairment possibly via impaired insulin- 
mediated augmentation of endothelium- dependent 
vasodilation, enhanced generation of reactive oxygen 
species and/ or excessive free fatty acids release from 
adipose tissue [12-16].  
 
When administered in humans via the nasal route, 
insulin has been shown to distinctly alter brain 
functions, without being absorbed into the blood stream 
or having direct systemic effects on peripheral blood 
glucose or insulin levels [17]. Thus, the nasal route 
provides a safe and effective way of conveying insulin 
to the brain to specifically modulate brain insulin action 
and exert beneficial effects.  
 
In this proof of principle, randomized, placebo-
controlled trial, we investigated the effects of intranasal 
insulin administration on cerebral blood flow and 
perfusion in healthy older and young adults. 
 
RESULTS 
 
Characteristics of the study subjects are shown in Table 
1. The mean age of the older adults was 65.2 (range 60-
69) years while the mean age of the younger adults was 
22.3 years (range 20-26 years). The average BMI was 
similar in both groups of adults. For the younger adults, 
mean systolic blood pressure (SBP) was 125 mmHg 
(SD 9.3) and diastolic blood pressure (DBP) 74.5 
mmHg (SD 7.2). For the older adults, mean SBP was 
156 mmHg (SD 22.7) and mean DBP was 90.4 mmHg 
(SD 7.9). Fasted glucose, fasted insulin and HOMA 
index of insulin resistance were all within normal 
reference ranges for both groups of adults.  
 
Plasma glucose and insulin trajectories 
 
We measured the peripheral (venous) glucose and 
insulin trajectories throughout an experimental period of 
90 minutes, which comprised measurements before, 
during and after MRI scanning. As shown in Figure 1, 
the trajectories of blood glucose and insulin were 
similar and stable in insulin compared to placebo 
conditions throughout the experimental period, both in 
young and older adults. In the young adults, the mean 
(SD) glucose and insulin levels over the 90- minute 
period were 4.57 (0.3) mmol/L and 5.25 (2.7) mU/L 
respectively under placebo condition, while the mean 
(SD) glucose and insulin levels were 4.61 (0.5) mmol/L 
and 5.71 (2.6) mU/L respectively under insulin 
condition. Likewise, in the older adults, the mean (SD) 
glucose and insulin levels over the 90- minute period 
Table 1. Characteristics of study subjects. 
 Young  Older 
Demographics N = 8  N = 11 
    Age (years) 22.3 (1.8)  65.2 (3.3) 
    BMI (kg/m2) 23.6 (2.2)  24.1 (2.2) 
    Alcohol intake (units/week) 14.4 (2.2)  9.77 (1.7) 
    Systolic BP (mmHg) 125 (9.3)  156 (22.7) 
    Diastolic BP (mmHg) 74.5 (7.2)  90.4 (7.9) 
    Hypertension, n (%) 0 (0)  2 (18.2) 
Metabolic     
    Fasted glucose (mmol/L) 4.83 (0.24)  5.14 (0.57) 
    Fasted Insulin (pmol/L)* 5.3 (4.83, 6.58)  4.63 (2.9, 8.23) 
    HOMA-IR index* 1.21 (1.0, 1.49)  1.05 (0.65, 2.03) 
Unless otherwise indicated, values are means (standard deviation). BMI: body mass index. BP: 
blood pressure. * Median (IQR). 
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were 4.87 (0.5) mmol/L and 5.75 (3.4) mU/L 
respectively under placebo condition, while the mean 
(SD) glucose and insulin levels were 4.87 (0.5) mmol/L 
and 5.30 (3.6) mU/L respectively under insulin 
condition. 
 
Quantitative flow 
 
The mean flow through the main cerebropetal arteries 
supplying the brain after intranasal application of 
insulin compared to placebo in both the older and 
younger adults is presented in Table 2. Intranasal 
application of insulin did not significantly change mean 
blood flow through the cerebropetal arteries in either 
older adults nor in the young. The mean difference in 
total quantitative flow under insulin minus placebo 
conditions in the younger adults was 0.35 ml/sec (SD 
2.59), while that of the older adults was -0.24 ml/sec 
(SD 1.66).  
 
The variance (standard deviations) around the mean 
flow were consistently lower after insulin 
administration. A Levene’s test verified the inequality 
of the variances in total quantitative flow after 
intranasal application of insulin compared to placebo 
when data from young and old adults were combined 
(P=0.047). Similar trends towards lower variances in 
cerebral blood flow after intranasal insulin application 
were observed in young and older adults. 
 
ASL perfusion 
 
Perfusion through specific cortical regions of the gray 
matter is shown in Table 3. In addition to cortical 
 
 
Figure 1. Glucose and insulin trajectories during the experimental period. Concentrations (every 10 minutes) of glucose and 
insulin in blood serum over a 90- minute period, comprising measurements before and after intranasal application of insulin (40IU 
insulin Actrapid, blue line) or placebo (saline, red dotted line) using ViaNase nasal atomizer. Blue arrow indicates timing of intranasal 
administration of insulin or placebo. Data is presented as mean with standard error in (A) glucose trajectory in young and (B) insulin 
trajectory in young (C) glucose trajectory in older and (D) insulin trajectory in older adults. 
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regions, we also assessed perfusion in the thalamus and 
the hypothalamus. In younger adults, perfusion through 
the whole brain gray matter, frontal, parietal, temporal 
and occipital gray matter regions after intranasal 
administration of insulin was not significantly different 
when compared to placebo. In younger adults, 
intranasal administration of insulin did not change 
perfusion in the thalamus or in the hypothalamus.  
 
In older adults, intranasal administration of insulin 
significantly increased perfusion through the occipital 
gray matter with 6.5% when compared to the 
Table 2. Quantitative flow through cerebropetal arteries. 
 Young  Older 
 Placebo 
Mean ± SD 
Insulin 
Mean ± SD 
p-value  Placebo 
Mean ± SD 
Insulin 
Mean ± SD 
p-value 
Arterial Flow         
Basilar artery 3.36 ± 0.74 3.15 ± 0.42 0.376  2.91 ± 0.91 2.78 ± 0.63 0.313 
Left carotid artery 4.44 ± 1.12 4.60 ± 0.78 0.745  4.48 ± 0.86 4.63 ± 0.69 0.537 
Right carotid artery 4.24 ± 1.13 4.66 ± 0.81 0.263  4.64 ± 1.26 4.39 ± 0.75 0.532 
Total flow 12.05 ± 2.73 12.40 ± 1.68 0.713  12.04 ± 2.26 11.8 ± 1.10 0.667 
Cerebral blood flow (in ml/sec) ± Standard deviation (SD) through cerebropetal arteries in insulin conditions 
compared to placebo in young and older adults.  
 
Table 3. ASL perfusion through different brain regions. 
 Young  Older 
 Placebo 
Mean ± SD 
Insulin 
Mean ± SD 
p-value  Placebo 
Mean ± SD 
Insulin 
Mean ± SD 
p-value 
Brain regions       
Whole brain 65.79 ± 11.69  67.53 ± 5.58 0.488  57.53 ± 8.0 59.0 ± 9.77 0.292 
Frontal GM  74.93 ± 13.67 76.64 ± 5.52 0.603  63.11 ± 8.19 63.90 ± 10.72 0.653 
Temporal GM  62.48 ± 10.82 64.39 ± 7.47 0.405  55.83 ± 7.22 55.74 ± 9.22 0.959 
Parietal GM  77.2 ± 14.87 78.66 ± 7.04 0.653  66.35 ± 10.95 69.22 ± 11.51 0.034 
Occipital GM  67.67 ± 13.21 68.27 ± 8.97 0.837  61.20 ± 10.11 65.15 ± 11.0 0.001* 
Thalamus 65.43 ±10.27 65.84 ± 9.89 0.831  63.31 ± 6.84 68.28 ± 6.75 0.003* 
Hypothalamus 43.97 ± 8.64 42.31 ± 6.43 0.603  38.31 ± 5.25 42.51 ± 6.43 0.156 
Perfusion (ml/100g/min) ± Standard deviation (SD) through the whole brain, four major cortical gray matter regions, 
and subcortical regions in insulin conditions compared to placebo in young and older adults as measured by 
continuous arterial spin labelling. GM: gray matter. *= Remained significant after Bonferroni corrected threshold for 
significance has been set as 0.007. 
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administration of placebo (Table 3, P=0.001). Perfusion 
through the parietal gray matter was 4.3% increased 
after intranasal administration of insulin (P=0.034). 
Perfusion in the frontal and the temporal gray matter 
regions was not significantly changed after intranasal 
administration of insulin (Table 3). In older adults, 
intranasal administration of insulin significantly 
increased perfusion in the thalamus (P=0.003), but no 
significant changes were found for perfusion in the 
hypothalamus. After application of Bonferroni corrected 
significance threshold of P<0.007, only the changes in 
occipital grey matter and the thalamus remained 
significant. The change in perfusion after intranasal 
application of insulin for one representative participant 
is visualized in the gray matter perfusion map shown in 
Figure 2.  
In addition to the whole gray matter regions, we also 
investigated the perfusion through the right and left 
hemisphere of each region of interest (ROI) separately. 
The directions of observed effects in the left/right ROIs 
were comparable to those observed for the whole lobe 
ROIs. For example, in older participants perfusion in 
the right parietal region under placebo compared to 
insulin condition was 65.58 ± 11.70 compared to 68.31 
± 11.17 (p=0.061); and perfusion in the left parietal 
region under placebo compared to insulin condition was 
67.12 ± 10.41compared to 70.12 ± 12.71 (p=0.221). 
Similarly, in older participants perfusion in the right 
occipital region under placebo compared to insulin 
condition was 60.92 ± 11.07 compared to 65.15 ± 10.97 
(p=0.006); and perfusion in the left occipital region 
under placebo compared to insulin condition was 61.49 
 
 
Figure 2. Gray matter perfusion maps after intranasal administration of placebo and insulin. Left panel (A and B) 
represents the gray matter perfusion map after intranasal placebo administration and the  right panel (C and D) the perfusion map 
after intranasal insulin administration for one representative older participant. The top row shows an increase in the gray matter 
perfusion of occipital lobe (illustrated by blue oval) after intranasal administration of insulin compared to placebo. The bottom row 
shows an increase in gray matter perfusion in the parietal lobe (illustrated by blue rectangle) after intranasal administration of insulin 
compared to placebo. Only the gray matter was included for calculation of perfusion after intranasal administration of insulin 
compared to placebo. 
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± 9.35 compared to 65.13 ± 11.61 (p=0.005). Likewise, 
in older participants perfusion in the right thalamus 
under placebo compared to insulin condition was 63.79 
± 6.72 compared to 68.52 ± 6.14 (p=0.008); and 
perfusion in the left thalamus under placebo compared 
to insulin condition was 62.84 ± 7.11 compared to 68.03 
± 7.63 (p=0.005).  
 
Analyses were repeated after exclusion of two older 
subjects that were hypertensive. The results did not 
materially change after exclusion of the two 
hypertensive older subjects. 
 
Figure 3 shows the paired gray matter perfusion in the 
parietal and occipital lobes and in the thalamus for 
every individual subject separately to illustrate 
individual differences between the placebo and insulin. 
 
DISCUSSION 
 
This proof of principle study was aimed at exploring the 
effects of intranasal application of insulin on cerebral 
blood flow and perfusion in healthy young and older 
adults. We found no effect of intranasal insulin 
application on total quantitative flow, or on flow in the 
basilar, left or right carotid arteries, in either young nor 
older adults. However, region specific analysis 
indicated that intranasal insulin application increased 
perfusion in the occipital gray matter region and in the 
thalamus in older adults. 
 
Due to the presence of direct pathways from the nasal 
cavity to the CNS, insulin can be delivered non- 
invasively rapidly to the CNS through the intranasal 
route without spilling over to the periphery. The 
intranasal route of insulin administration thus bypasses 
uptake into the bloodstream and so circumvents the risk 
of systemic hypoglycemia that is associated with 
peripheral administration. We found that blood glucose 
and insulin levels did not change after intranasal 
administration. This is in line with previous studies that 
show that plasma glucose concentrations remain 
unchanged after intranasal application of 40IU insulin 
[25, 26]. It further strengthens the fact that intranasal 
administration can safely be used for selectively 
increasing cerebral insulin levels. 
 
One of the regions where insulin becomes readily 
available is the cerebral cortex, which is bathed by CSF, 
to which intranasally administered insulin has direct 
access [19]. There is evidence of bulk flow transport of 
peptides through extracellular pathways from the nasal 
cavity to the CNS, including cerebral cortex, gray 
matter and other parts of the CNS, via both olfactory 
and trigeminal pathways [27]. In the upper nasal cavity, 
olfactory neurons are exposed such that their axons 
project through the cribriform plate to the olfactory 
bulb. When inhaled, insulin accesses the CNS 
parenchyma either through the cribriform plate along 
the olfactory neurons or through perivascular channels 
associated with the olfactory or trigeminal systems [28]. 
In literature, different studies have used varying doses 
(10, 20, 40, 60 IU or 160IU) of insulin to elicit effects 
on CBF. In our study, we used 40IU of insulin. This 
dose was chosen based on the instrument that we used 
 
Figure 3. Paired individual gray matter perfusion 
measurements for placebo and insulin conditions. 
Left panel represents the gray matter perfusion in the 
parietal lobe as paired data for placebo and intranasal 
insulin per individual subject in the young and the older 
group. The right panel represents the gray matter 
perfusion in the occipital lobe. 
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for insulin delivery. We used the ViaNase intranasal 
insulin device, which had been specifically designed to 
maximise drug transport  to the central nervous system 
after delivery to the olfactory region. This device has 
been used extensively in literature, usually at a dose to 
of 20IU or 40IU of insulin, and has been shown to elicit 
beneficial effects on various endpoints, both in healthy 
persons and patients with Alzheimer’s disease [25, 26]. 
 
Few studies have been performed to study the effect of 
intranasal application of insulin on regional blood flow 
in the brain. A recent study done in eight healthy young 
adults found no effect of 160IU intranasal insulin 
application on cerebral blood flow in the visual cortex, 
neither at baseline nor when cerebral blood flow was 
measured after specific tasks [20]. On the other hand, 
another study that was performed in a larger group of 
participants (25 lean, 10 overweight and 23 obese 
persons) of unspecified age found that 160IU intranasal 
insulin led to CBF decrease in the hypothalamus [29]. 
In our study, we found no effect of intranasal insulin 
application on flux in the major vessels, neither in 
young healthy men, nor in older men. It is possible that 
we missed a small effect of insulin on CBF because of 
the limited number of subjects in our study. 
Furthermore, since the positive finding in the 
aforementioned study was after administration of 160IU 
of insulin, it is possible that our dose of 40IU did not 
increase insulin concentration in the CNS sufficiently 
enough to effect changes in CBF.  
 
While quantitative flow in the major arteries did not 
increase after intranasal application of insulin, we found 
that after intranasal insulin application, tissue perfusion 
was increased in the thalamus and in the occipital cortex 
(by 6.5%) in older adults. An increase of 4.3% was also 
found in parietal cortex in older adults, but which did 
not reach significance after strict correction for multiple 
comparisons. The occipital lobe is the visual processing 
center. It contains mainly the visual cortex and the 
ventral stream of vision that enables ability to focus on 
motor actions in response to outside stimuli. Next to the 
occipital lobe, the parietal lobe integrates sensory 
information among various modalities, including 
proprioception, mechanoreception, and visuospatial 
processing. The posterior parietal cortex, also referred 
to as the dorsal stream of vision, receives 
somatosensory and/or visual input that can be 
transmitted to motor signals. In a previous study done in 
48 subjects with a mean age of 24 years, perfusion was 
increased in the insular cortex, an area closely related to 
the parietal cortex, after intranasal insulin 
administration [22]. Somewhat similar to the parietal 
cortex, the insular cortex also integrates information 
from other sensory modalities and contains 
topographically organized visceral sensory 
representation. We also observed that intranasal insulin 
application increased perfusion of the thalamus. The 
thalamus receives information from almost all sensory 
systems and relays the information to associated cortical 
areas. From literature, increased cerebral blood flow has 
been linked to vasodilatation around the active area due 
to increased energy demand [30]. Also, insulin has been 
shown to be a vasoactive modulator that regulates 
peripheral and cerebral blood flow possibly via a direct 
vasodilatory effect [11]. Taken together, our finding of 
increased perfusion in some brain areas would support 
the hypothesis that intranasal insulin application might 
restore energy demand and neuronal activity in these 
regions [7, 31].  
 
This exploratory study is the first placebo-controlled, 
cross- over study in older and young adults showing 
that intranasally administered insulin increased regional 
perfusion in the occipital brain region and in the 
thalamus of older adults, as measured with a non- 
invasive ASL technique. Strength of our study is the 
cross-over design in which the participants were their 
own controls, thus minimizing the confounding effects 
of between- person differences. Moreover, both the 
young and older participants were included with strict 
in- and exclusion criteria. Thus, the characteristics of 
adults in both the young and older participant groups 
were homogenous, making them comparable within the 
group. On the other hand, this study has some 
limitations. It is limited by its sample size, especially of 
the younger age group, and the inclusion of males only. 
Thus, we cannot rule out that insulin has effect on many 
other brain areas, since several previous studies have 
demonstrated that insulin had beneficial effects on brain 
function including memory, cognition [32-34], and 
brain mediated functions such as postprandial 
thermogenesis and other metabolic profiles [31, 35-37]. 
Thus, other brain regions could have gone undetected 
because of the small sample size. We also cannot 
exclude the possibility that effects of intranasal 
administration of insulin may be sex specific. Indeed, 
sex-specific effects of intranasal administration of 
insulin have been observed for other endpoints, 
including reduction of body weight [36]. It is also a 
limitation that the clinical significance of the observed 
increases in CBF remains to be determined. Taken 
together, larger sufficiently powered studies are needed 
to delineate the exact effects of insulin on cerebral 
blood flow and perfusion in both the cortical brain 
regions and in subcortical structures in both males and 
females and in both young and older adults and to relate 
these to clinically significant outcomes.  
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MATHERIALS AND METHODS 
 
Ethics statement 
 
This study titled “Maintaining health in old age through 
homeostasis: Switchbox Phase II” was approved by the 
Medical Ethical Committee of Leiden University 
Medical Center under protocol P13.164 and the Dutch 
competent authority (Centrale Commissie 
Mensengebonden Onderzoek (CCMO)) with protocol 
code number  NL45043.058.13. The study is registered 
in the European Clinical Trials Database under number 
2012-005650-29. All investigations have been 
conducted according to the principles expressed in the 
Declaration of Helsinki. All participants provided 
written informed consent after written and verbal 
description of the study was given. 
 
Trial design and participants 
 
The design is a double-blinded, randomized, cross-over, 
placebo controlled trial in volunteers from the general 
population. This study was aimed at examining the 
effects of intranasal insulin on circulatory metabolic and 
endocrine parameters, as well as on resting and 
functional brain activities using MRI, in older and 
young adults. Fourteen elderly and nine young 
relatively healthy men (age criteria 60-85 years for 
older adults and 18-35 years for young adults), with a 
body mass index (BMI) between 20 kg/m2 and 27 
kg/m2 were recruited from the general population. 
Exclusion criteria included fasting plasma glucose 
above 7 mmol/l, anemia (haemoglobin < 7.1 mmol/l), 
presence of anatomic deviations of the nose, any 
significant endocrine, neurological and cardiovascular 
diseases, or use of medication known to influence 
lipolysis, thyroid function, glucose metabolism, 
GH/IGF-1 secretion or any other hormonal axis. 
Furthermore, persons with a current smoking or alcohol 
addiction or history of substance abuse were excluded. 
Of the 23 participants that were contacted via telephone, 
three (older) participants were excluded after screening. 
The reasons for exclusion were uncontrolled high blood 
pressure (n=1) and renal insufficiency (n=2). Of these, 
all participants except for one (young) successfully 
completed the study. The reason for the drop-out was 
phobia for cannulas/ blood withdrawal. 
 
Randomization, masking and intervention 
 
Randomization was carried out by the pharmaceutical 
trial coordinator, while the researchers were blinded to 
what the participants received. Concealment of 
treatment allocation was ensured by delivery of trial 
medication in a standard plain vial (same for all 
treatment groups) that had been prepared and re-labelled 
by the hospital pharmacy. De-blinding was done at the 
end of the study.  
 
The study interventions consisted of intranasal 
application of 40 IU insulin (Actrapid; Novo Nordisk, 
Mainz, Germany) or placebo (Sterile saline), delivered 
using the ViaNase Electronic Atomizer (Kurve 
Technology inc.). The ViaNase device had been 
specifically designed to deliver drugs to the olfactory 
region to maximize drug transport to the central nervous 
system. The device released a metered insulin (40 IU) 
or saline dose directly into the subject’s nostrils. A total 
volume of 0.4 mL (0.2 ml per nostril) was administered, 
which was inhaled by breathing evenly over a 2-minute 
period. In both right and left nostril, two doses each 
were delivered resulting in a total insulin dose of 40 IU. 
This method allowed administration of smaller particle 
sizes to increase drug deposition in the upper nasal 
cavity without transporting the drug to the lungs [18].  
 
For the current study, results from two study visits, 
spaced apart by a week, on one of which they received 
insulin and on the other placebo, in a randomized 
manner were compared. All participants underwent 
exactly the same protocol during both study visits.  
 
Experimental protocol 
 
In the morning after a 10-hour overnight fast, 
participants arrived at the MRI facilities at 08.00 in the 
morning. A catheter was placed in a vein of the forearm 
of the non-dominant hand. First, a baseline venous 
blood sample was collected in a serum-separator (SST)-
tube. Thereafter, every 10 minutes, 4 ml of blood was 
collected into a SST-tube and 2 ml into K3-EDTA tube. 
Ten minutes after the first blood withdrawal, the trial 
medication (placebo or 40 IU of insulin) was 
administered intranasally, under the supervision of the 
experimenter, with a ViaNase Electronic Atomizer. 
Participants were asked if they noticed a specific smell 
or noticed something about the applied treatment. 
However, participants were not informed that the smell 
could be associated with the treatment and therefore 
would remain unaware of the applied intervention. We 
checked this by questioning the participants of the 
awareness of the treatment condition and this did not 
coincide with the actual applied treatment after de-
blinding of the study. About 20 minutes after the 
intranasal application, participants were transferred into 
the MRI for the scanning procedure (Figure 4). About 
30 min after the intranasal application, the CBF 
measurement was performed in the MRI scanner. This 
time interval was chosen because previous studies have 
shown that it takes 30 minutes for insulin to reach 
maximal concentrations in the CSF [19], and a similar 
time window has been used previously in other studies 
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where brain – related effects of intranasal insulin were 
studied [20-22]. 
 
Anthropometrics 
 
During the first study day, height, weight, percentage of 
body fat, and waist and hip circumference of 
participants were measured. Weight (in kilograms) was 
divided by the squared height (in meters) to calculate 
the BMI.  
 
Blood sampling and chemical analysis of blood 
samples 
 
After each withdrawal, the K3-EDTA tubes were 
immediately placed on ice before centrifugation, 
whereas the serum tubes were kept at room temperature 
and centrifuged when the samples were clotted, usually 
between 30–60 minutes. Samples were centrifuged at 
3520 RPM at 4 °C for 10 minutes. The EDTA plasma 
and serum samples were stored in two aliquots of 500 µl 
during the rest of the sampling at − 20 °C. After the 
sampling they were transferred to a − 80 °C freezer and 
stored until analysis.  
 
All laboratory measurements were performed with fully 
automated equipment and diagnostics from Roche 
Diagnostics (Almere, The Netherlands). Glucose levels 
were measured using Hitachi Modular P800 from 
Roche (Almere, the Netherlands), with coefficient of 
variation (CV) for measurement less than 1%. Insulin 
levels were measured using the Immulite 2500 from 
DPC (Los Angeles, CA). CV was less than 6%.  
Brain MRI protocol 
 
The perfusion measurement reported in the current 
study was part of a longer scanning protocol  (48 
minutes in young participants and 24 minutes in older 
participants) in which we aimed to successively assess 
several MRI endpoints. Scans were performed on a 
whole body magnetic resonance system with a 3 Tesla 
field strength (Philips Medical Systems, Best, the 
Netherlands). 3D T1-weighted images were acquired 
with the following imaging parameters: echo time (TE) 
4.6ms, repetition time (TR) 9ms, Flip 8°, field of view 
(FOV) = 224 × 177 × 168mm, scan duration ~5minutes. 
The pseudo Continuous Arterial Spin Labeling 
(pCASL) with TE/TR/Flip: 14ms/4.0s/90°, FOV 240 x 
133 x 240mm, matrix 80 x 80mm, slices 19, labeling 
duration of 1650 ms, post labeling delay ranging from 
1525 ms for the most inferior slice to 2155 ms for the 
most superior slice scan, total scan duration 6 minutes. 
The M0-scan with TE/TR/flip: 14ms/6.0s/90, FOV 
240x133x240, Matrix 80 80, slices 19, scan duration 30 
seconds. The pCASL labelling slice was positioned 
perpendicular to the common carotid arteries right 
below the bifurcation point of common carotid into the 
internal and external carotid artery. The phase-contrast 
quantitative flow (QF) scan was planned using 2 
localizer angiograms in the sagittal and coronal planes 
and acquired with the following parameters: TR = 
11ms; TE 7.5ms; flip angle = 10°; slice thickness = 
5mm; field of view 150x103mm; voxel size 
1.17x1.17mm; velocity sensitivity = 200cm/s, 20 signal 
averages. Time allocated to measure perfusion was 6 
minutes. 
 
 
Figure 4. Flowchart of experimental procedures related to cerebral blood flow and perfusion measurements. After an 
overnight fast and baseline measures, the study day started at 08.00 with blood sample withdrawal for baseline measures, after 
which subjects received either the intranasal insulin or intranasal placebo treatment. MRI scanning began 20 mins later, including 
survey/structural MRI scans, flow and perfusion scans.  
 
www.aging-us.com 799 AGING  
Phase contrast MR Angiography 
 
Quantitative flow measurements were performed using 
ungated phase-contrast MRA, based on 2 localizer MR 
angiograms in the sagittal and coronal orientation as 
shown in Figure 5. A region of interest (ROI) was 
drawn around the vessel lumen on the magnitude 
images by an experienced rater using Philips Software 
on a PACS (Philips Medical Systems, Best, The 
Netherlands) workstation with ROI measurement tools. 
Flux was measured for basilar artery and both internal 
carotid arteries separately. Total flux was calculated for 
all three vessels together. 
 
pCASL quantitative analysis 
 
MR images were analyzed using FMRIB Software 
Library (FSL) (Analysis Group, FMRIB, Oxford, UK). 
[23] The perfusion was measured in the partial volume 
corrected gray matter volume. pCASL scans were 
performed in a total time of 6 minutes.  pCASL images 
were first corrected for slice timing, gradient 
nonlinearities and subject motion using in-house 
software and different tools of the FMRIB Software 
Library (FSL) version 5.0.6. 
 
Files were smoothed and after subtraction a mean CBF 
over the entire 6- minute pCASL scan was calculated, 
yielding one average perfusion map for the 6- minute 
scan. This map was then translated to MNI152 space 
using FLIRT and FNIRT with the conversion matrix 
based on the 3DT1 scans. The perfusion was measured 
in the corrected gray matter volume. This corrected gray 
matter was segmented in four cortical areas based on 
the Harvard Oxford probabilistic cortical atlas threshold 
of 25 percent [24]. These ROI templates were 
subsequently used with each subject’s gray matter mask 
to calculate the mean gray matter CBF in units of 
mL/100g/min for each anatomical region. Perfusion in 
the hypothalamus and thalamus was calculated in a 
similar way by measuring perfusion on the CBF maps 
in thalamic/hypothalamic ROI using Harvard oxford 
atlas ROI templates for these regions.  
 
One participant was noticed to have extremely tortious 
blood vessels. For this participant, it was difficult to 
draw a consistent region of interest for phase contrast 
MR Angiography. For same reason, he also had 
strongly decreased ASL labelling efficiency. He was 
excluded from subsequent analyses. 
 
Statistical Analysis 
 
Descriptive statistics were used to summarize the 
characteristics of both study groups. Homeostatic model 
assessment of insulin resistance (HOMA-IR) was 
calculated by the product of the fasting insulin level 
(mU/L) and the fasting glucose level (mmol/L) divided 
by 22.5.  
 
The relation between intranasal insulin and cerebral 
blood flow was determined using paired t-tests, and 
presented as means with standard deviation with 
corresponding p-values. Homogeneity of variance 
assumption was tested using Levene’s test. Correction 
for inter- individual and intra- individual differences in 
perfusion was done by calculating normalized gray 
matter volumes according to MNI standard space 
registration. For statistical analyses, Statistical Package 
for Social Sciences (SPSS) software for windows 
 
 
Figure 5. MR images of the vasculature measured with phase contrast MR angiography imaging for Quantitative Flow 
(QF). Typical placement of the QF phase-contrast slice (C) through the right internal carotid artery (RCAR), left internal carotid artery 
(LCAR) and the basilar artery (BAS) using the sagittal (A) and coronal (B) localizer angiograms. ROI’s were drawn around the three 
arteries in slice C to measure flow. 
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(version 20.0) was used. Statistical significance was set 
as P< 0.007, which is the corrected threshold for 
significance after Bonferroni correction for multiple 
comparisons. 
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